Form D · Biotechnology

Relmada Therapeutics, Inc.

New York, NY · CIK 0001554535

Offering snapshot reported May 22, 2014 · SEC filing

Reported sold: $15.1M
Investors reported: 225
Minimum accepted: $100K
First sale: May 12, 2014

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
May 22, 2014	Initial	$15,051,110	No comparison	225	SEC filing
Jun 7, 2013	Initial	$180,000	No comparison	6	SEC filing
Jun 6, 2013	Amendment	$4,955,500	$1,947,500vs Jul 23, 2012	98	SEC filing
Jul 23, 2012	Initial	$3,008,000	No comparison	61	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $1.81M
Finders' fees: $0
Form D file number: 021-217828

Included in the sales commission amount is a non-accountable 2% allowance for expenses paid to the agent. The agent also received warrants to purchase 25,085,183 shares of common stock of the issuer.

Sales compensation recipients

Scroll to see all columns →

Recipient	CRD	Associated broker-dealer
Laidlaw & Company (UK) Ltd.	119037

Source: Form D, filed May 22, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Shreeram Agharkar	Director
Najib Babul	Director, Executive
Douglas Beck	Executive
Eliseo O. Salinas	Executive
Sandesh Seth	Director
Sergio Traversa	Director, Executive
Nabil M. Yazgi	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

546 Fifth Avenue 14 Th Floor
New York, NY, 10036